Alessandro Francesco Mistretta
Papers
1
Total Citations
12
H-Index
1
About
Alessandro Francesco Mistretta is a urologic oncologist whose research centers on refining risk stratification and surgical outcomes for prostate cancer, with a particular focus on low-risk disease and active surveillance. His major contributions include the development and validation of the Prostatic Systemic Inflammatory Markers (PSIM) score, a novel tool that leverages routine blood-based inflammatory markers—lymphocyte, platelet, and neutrophil counts—to predict adverse pathologic features at robotic radical prostatectomy. In his landmark 2021 cohort study, Mistretta demonstrated that the PSIM score can identify which patients with low-risk prostate cancer, despite meeting active surveillance criteria, harbor more aggressive disease requiring immediate intervention. This work, cited 12 times, offers a practical, cost-effective adjunct to traditional risk models, potentially sparing men from undertreatment or unnecessary delays. By integrating systemic inflammation into preoperative decision-making, Mistretta’s research bridges immunology and surgical oncology, providing clinicians with a readily accessible tool to personalize care. His findings underscore the importance of biological markers beyond standard clinical parameters, advancing the precision of prostate cancer management and informing future studies on inflammatory signatures in urologic malignancies.
Research Focus
Key Achievements
Top Papers
- 1